ロード中...
Efficacy gap between phase II and subsequent phase III studies in oncology
AIMS: There is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all. This paper investigated the relation between phase II and III clinical trial efficacy in oncology....
保存先:
| 出版年: | Br J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7318994/ https://ncbi.nlm.nih.gov/pubmed/32034790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14237 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|